Tuesday 13 October 2026
Export CAPR’s income statement to Excel — free account
Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.
6.88
0.59
−7.90%
Follow CAPR
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 1 | 3 | 3 | 3 | 4 | 3 | 4 | — |
P/E ratio |
0.00 | 52.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
11.83 | 13.66 | 7.21 | 4.73 | 172.12 | 223.49 | 34.30 | 5.45 | 21.82 | — |
Altman Z-Score |
(4.66) | (1.49) | (12.89) | (9.87) | 1.20 | (0.31) | (3.79) | (2.15) | 10.32 | — |
Altman Z″-Score (non-manufacturers) |
(11.03) | (7.64) | (28.50) | (19.12) | (0.52) | (3.49) | (10.05) | (8.76) | 6.08 | — |
P/FCF ratio |
0.00 | 0.00 | 1.37 | 0.25 | 0.00 | 0.00 | 60.72 | 0.00 | 9.30 | — |
Beneish M-Score |
(3.85) | 3.38 | (3.46) | (3.62) | — | — | 0.79 | 6.51 | (2.61) | — |
P/Operating CF |
(13.60) | (13.65) | (3.20) | (2.66) | (13.90) | (12.02) | (13.70) | (11.83) | (32.85) | — |
P/B ratio |
0.00 | 3.24 | 2.61 | 0.69 | 1.89 | 2.16 | 8.02 | 6.07 | 3.34 | — |
Price to Tangible BV |
0.00 | 3.27 | 2.64 | 0.70 | 1.89 | 2.16 | 8.02 | 6.07 | 3.34 | — |
EV/Sales |
10.92 | 18.60 | 19.49 | 12.33 | 112.70 | 155.13 | 24.42 | 4.44 | 15.66 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(3.02) | (3.49) | (2.35) | (1.82) | (3.48) | (2.79) | 13.69 | (4.37) | (8.72) | — |
EV/FCF |
(2.98) | (3.48) | 3.69 | 0.65 | (4.60) | (2.61) | 43.23 | (4.04) | 6.67 | — |
Quick Ratio |
3.63 | 9.10 | 6.17 | 11.11 | 10.99 | 8.53 | 1.78 | 1.59 | 7.70 | 8.88 |
Current Ratio |
3.70 | 9.40 | 6.75 | 11.74 | 11.33 | 8.82 | 1.82 | 1.63 | 7.77 | 9.01 |
Net Debt/EBITDA |
0.22 | 0.90 | 0.27 | 0.86 | 2.41 | 1.69 | 1.42 | 1.72 | 3.68 | 2.99 |
Debt/Assets |
74.18% | 20.75% | 36.51% | 30.38% | 0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(3.47) | 0.30 | 0.73 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.23 | 0.15 | 0.13 | 0.10 | 0.01 | 0.01 | 0.06 | 0.46 | 0.19 | 0.00 |
Operating CF/Net income |
0.77 | (5.85) | 0.91 | 0.89 | 0.74 | 0.84 | (0.17) | 1.15 | 0.99 | 0.66 |
Capex/Depreciation |
(1.54) | (0.22) | 143.84 | 17.44 | (3.81) | (4.87) | (6.30) | (1.92) | 64.73 | 131.75 |
Interest Coverage |
(49.25) | (32.25) | (112.70) | — | — | (364.15) | (56.95) | — | — | (35.51) |
| 747.04% | 67.32% | (191.78%) | (133.42%) | (77.95%) | (67.23%) | (134.49%) | (129.63%) | (48.16%) | (46.56%) | |
| (108.03%) | 13.89% | (119.05%) | (75.06%) | (59.73%) | (52.73%) | (63.48%) | (40.96%) | (35.31%) | (39.91%) | |
ROIC |
0.00% | 0.00% | (2,130.18%) | (1,463.42%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(137.79%) | 16.87% | (195.00%) | (75.74%) | (43.28%) | (58.72%) | (121.47%) | (88.63%) | (27.36%) | (34.39%) |
Average Days of Receivables |
20.38 | 47.17 | 44.75 | 31.96 | 0.00 | 583.94 | 78.34 | 150.36 | 169.93 | 0.00 |
Research and Development Expense of Revenue |
401.19% | 403.78% | 721.96% | 511.62% | 2,725.43% | 5,541.45% | 855.07% | 144.76% | 224.37% | 0.00% |
Selling, General and Administrative Expense of Revenue |
123.37% | 178.62% | 295.06% | 357.92% | 1,786.40% | 3,108.33% | 408.85% | 50.87% | 66.75% | 0.00% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
49.08% | 64.16% | 103.24% | 69.75% | 629.29% | 1,210.98% | 174.74% | 29.36% | 43.85% | 0.00% |
Graham Net Nets |
(0.10) | 0.29 | 0.32 | 1.32 | 0.51 | 0.39 | 0.05 | 0.11 | 0.28 | — |
Graham Number |
22.25 | 5.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(40.00%) | 1.91% | (129.27%) | (168.75%) | (27.41%) | (29.69%) | (30.65%) | (16.99%) | (8.70%) | — |
Free Cash Flow Yield |
(30.97%) | (39.17%) | 73.15% | 401.01% | (14.23%) | (26.62%) | 1.65% | (20.16%) | 10.75% | — |
Revenue per Share |
2.16 | 1.15 | 0.57 | 0.27 | 0.02 | 0.01 | 0.10 | 0.94 | 0.63 | 0.00 |
Operating CF per Share |
(7.79) | (6.14) | (4.71) | (1.84) | (0.65) | (0.73) | 0.20 | (0.96) | (1.14) | (1.50) |
Capex per Share |
(0.10) | (0.01) | 7.71 | 0.81 | (0.04) | (0.05) | (0.14) | (0.08) | 2.62 | 5.35 |
Free Cash Flow per Share |
(7.90) | (6.15) | 3.00 | (1.03) | (0.68) | (0.78) | 0.06 | (1.03) | 1.48 | 3.85 |
Cash per Share |
9.46 | 6.41 | 2.56 | 2.66 | 2.10 | 1.51 | 1.69 | 1.47 | 4.30 | 6.84 |
Shareholders Equity per Share |
(2.16) | 4.84 | 1.57 | 1.84 | 1.81 | 1.36 | 0.48 | 0.84 | 4.13 | 6.58 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.16) | 4.84 | 1.57 | 1.84 | 1.81 | 1.36 | 0.48 | 0.84 | 4.13 | 6.58 |
Free Cash Flow |
(14.65) | (14.26) | 8.82 | (3.82) | (10.60) | (18.01) | 1.56 | (27.64) | 52.26 | 179.06 |
Working Capital |
13.21 | 14.04 | 7.22 | 9.65 | 30.71 | 32.30 | 19.30 | 19.59 | 142.36 | 287.10 |
Capital Expenditures |
(0.19) | (0.03) | 22.68 | 3.00 | (0.55) | (1.20) | (3.36) | (2.05) | 92.26 | 248.87 |
Net Current Asset Value |
(4.64) | 10.67 | 3.84 | 6.27 | 27.26 | 26.47 | 4.58 | 14.72 | 138.37 | 272.78 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.05 | 0.01 | (13.57) | (2.99) | 1.76 | 4.88 | 1.32 | 0.08 | (4.14) | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.29 | 0.39 | 0.27 | 0.39 | 0.17 | 0.14 | 0.12 | 0.19 | 0.26 | 0.10 |
Cash ROIC |
(53.37%) | (48.40%) | 56.79% | (19.01%) | (17.40%) | (27.18%) | 2.93% | (44.52%) | 17.60% | 28.70% |
Accounts Receivable Turnover |
18.38 | 9.39 | 6.08 | 6.86 | 0.00 | 1.02 | 5.43 | 4.61 | 2.15 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.22 | 0.28 | 0.27 | 0.15 | — | 0.24 | 0.47 | 5.46 | 10.37 | 5.21 |
Average Payables |
3.21 | 2.60 | 1.46 | 1.08 | 1.81 | 3.22 | 4.32 | 5.59 | 4.77 | 2.47 |
Average Assets |
17.41 | 17.51 | 12.76 | 10.18 | 22.87 | 37.97 | 45.71 | 54.41 | 114.61 | 263.22 |
Average Common Equity |
(2.52) | 3.61 | 7.92 | 5.73 | 17.52 | 29.78 | 21.58 | 17.19 | 84.03 | 225.63 |
Columns are period end dates